Treatment of ovarian clear cell carcinoma with immune checkpoint blockade: a case series.

ABSTRACT:

Background

Although immune checkpoint blockade has demonstrated limited effectiveness against ovarian cancer, subset analyses from completed trials suggest possible superior efficacy in the clear cell carcinoma subtype.

Objective

To describe the outcomes of patients with ovarian clear cell carcinoma treated with immune checkpoint blockade.

Methods

This was a single-institution, retrospective case series of patients with ovarian clear cell carcinoma treated with a programmed cell death protein 1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor with or without concomitant cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibition between January 2016 and June 2021. Demographic variables, tumor microenvironment, molecular data, and clinical outcomes were examin

SUBMITTER: Sia TY 

PROVIDER: S-EPMC9356988 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature